Sheba study indicates only a minor, expected decline in antibody levels among recipients of the Pfizer-BioNTech vaccine
Two months after receiving the second dose of the Pfizer-BioNTech COVID-19 vaccine, 2,500 of Sheba Medical Center’s employees displayed high blood antibody levels according to a new Sheba study. While a minor decline in blood antibody levels was observed, Prof. Gili Regev-Yochay, Director of the Infectious Diseases Unit at Sheba, says that “this drop was expected, and should not cause alarm.”
Prof. Regev-Yochay added: “We observed blood antibody levels that were much higher than the required threshold in most of the study’s participants. The few participants that displayed a more significant drop are currently being examined to determine whether this drop is indicative of decreased protection against COVID-19 infection.
The initial study on the efficacy of the Pfizer-BioNTech vaccine also included the hospital staff and has shown that the initial results have shown high-level protection against the COVID-19. The study will continue, and participants will be tested again to determine blood antibody levels 3 months after receiving the second vaccine jab.